echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Xiansheng wins 3 billion large varieties of Roche and 60% of the market is in danger

    Xiansheng wins 3 billion large varieties of Roche and 60% of the market is in danger

    • Last Update: 2021-03-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network News on March 2 A few days ago, the NMPA official website showed that Simcere's mycophenolate mofetil capsules were approved and deemed to have been reviewed.
    According to data from Mi Nei.
    com, in 2019, the sales of mycophenolate mofetil in public medical institutions in China exceeded 3 billion yuan, and its sales in 2020H1 exceeded 1.
    6 billion yuan, an increase of 13.
    39% year-on-year.
     
    Mycophenolate mofetil is an immunosuppressant developed by Roche.
    It is suitable for preventing organ rejection in patients receiving allogeneic kidney or liver transplantation.
    It should be used with corticosteroids and cyclosporine or tacrolimus at the same time .
    According to Roche’s financial report, the company’s global sales of mycophenolate mofetil will be 606 million Swiss francs in 2020.
     
    Sales of mycophenolate mofetil at the terminal of public medical institutions in China
    Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
    According to data from Meinenet, in 2019, the sales of mycophenolate mofetil in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 3 billion yuan; in 2020H1, its sales exceeded 1.
    6 billion yuan, an increase of 13.
    39% year-on-year, of which Roche accounted for 60.
    7% of the market share, and Sino-US Huadong Pharmaceutical accounted for 34.
    39%.
     
      Mycophenolate mofetil capsules previously reviewed companies
      Source: Mi Nei Net Consistency Evaluation Database
     
      At present, mycophenolate mofetil capsules have been evaluated by 4 companies, including Hisun Pharmaceutical, Tianyin Pharmaceutical, Sino-US Huadong Pharmaceutical and Simcere Pharmaceutical.
    With the normalization of national centralized procurement, mycophenolate mofetil capsules are expected to be included in the fifth batch of centralized procurement.
     
      Data source: Mi Neiwang database
      Medical Network News on March 2 A few days ago, the NMPA official website showed that Simcere's mycophenolate mofetil capsules were approved and deemed to have been reviewed.
    According to data from Mi Nei.
    com, in 2019, the sales of mycophenolate mofetil in public medical institutions in China exceeded 3 billion yuan, and its sales in 2020H1 exceeded 1.
    6 billion yuan, an increase of 13.
    39% year-on-year.
     
      Mycophenolate mofetil is an immunosuppressant developed by Roche.
    It is suitable for preventing organ rejection in patients receiving allogeneic kidney or liver transplantation.
    It should be used with corticosteroids and cyclosporine or tacrolimus at the same time .
    According to Roche’s financial report, the company’s global sales of mycophenolate mofetil will be 606 million Swiss francs in 2020.
     
      Sales of mycophenolate mofetil at the terminal of public medical institutions in China
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      According to data from Meinenet, in 2019, the sales of mycophenolate mofetil in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 3 billion yuan; in 2020H1, its sales exceeded 1.
    6 billion yuan, an increase of 13.
    39% year-on-year, of which Roche accounted for 60.
    7% of the market share, and Sino-US Huadong Pharmaceutical accounted for 34.
    39%.
     
      Mycophenolate mofetil capsules previously reviewed companies
      Source: Mi Nei Net Consistency Evaluation Database
     
      At present, mycophenolate mofetil capsules have been evaluated by 4 companies, including Hisun Pharmaceutical, Tianyin Pharmaceutical, Sino-US Huadong Pharmaceutical and Simcere Pharmaceutical.
    With the normalization of national centralized procurement, mycophenolate mofetil capsules are expected to be included in the fifth batch of centralized procurement.
     
      Data source: Mi Neiwang database
      Medical Network News on March 2 A few days ago, the NMPA official website showed that Simcere's mycophenolate mofetil capsules were approved and deemed to have been reviewed.
    According to data from Mi Nei.
    com, in 2019, the sales of mycophenolate mofetil in public medical institutions in China exceeded 3 billion yuan, and its sales in 2020H1 exceeded 1.
    6 billion yuan, an increase of 13.
    39% year-on-year.
     
      Mycophenolate mofetil is an immunosuppressant developed by Roche.
    It is suitable for preventing organ rejection in patients receiving allogeneic kidney or liver transplantation.
    It should be used with corticosteroids and cyclosporine or tacrolimus at the same time .
    According to Roche’s financial report, the company’s global sales of mycophenolate mofetil will be 606 million Swiss francs in 2020.
     
      Sales of mycophenolate mofetil at the terminal of public medical institutions in China
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      According to data from Meinenet, in 2019, the sales of mycophenolate mofetil in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 3 billion yuan; in 2020H1, its sales exceeded 1.
    6 billion yuan, an increase of 13.
    39% year-on-year, of which Roche accounted for 60.
    7% of the market share, and Sino-US Huadong Pharmaceutical accounted for 34.
    39%.
    Hospital hospital hospital
     
      Mycophenolate mofetil capsules previously reviewed companies
    Enterprise business enterprise
      Source: Mi Nei Net Consistency Evaluation Database
     
      At present, mycophenolate mofetil capsules have been evaluated by 4 companies, including Hisun Pharmaceutical, Tianyin Pharmaceutical, Sino-US Huadong Pharmaceutical and Simcere Pharmaceutical.
    With the normalization of national centralized procurement, mycophenolate mofetil capsules are expected to be included in the fifth batch of centralized procurement.
     
      Data source: Mi Neiwang database
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.